Wave life sciences highlights growth strategy for building the leading rna medicines company in annual r&d day

Presented preclinical proof-of-concept data for new, wholly owned program targeting inhbe for metabolic disorders, including obesity, which uses wave's best-in-class galnac-sirna capabilities and novel genetic insights from gsk
WVE Ratings Summary
WVE Quant Ranking